It has been suggested that levodopa-induced involuntary movements result from stimulation of a subpopulation of hypersensitive striatal dopamine receptors (Klawans, 1973) . This has been supported by the evolution of some dyskinesia sequences which are independent of therapeutic effects (Barbeau, 1975; Lees et al., 1977) and emerging evidence for the existence of separate dopamine receptor mechanisms in the corpus striatum of animals (McLennan and York, 1967; Olson et al., 1972; Cools and Van Rossum, 1976) .
The therapeutic possibilities of selective dopamine receptor blockade led to the use of haloperidol (Klawans and Weiner, 1974) and pimozide (Tarsy et al., 1975) in the treatment of levodopainduced peak dose dyskinesias. Both drugs effectively suppressed involuntary movements but caused an unacceptable increase in disability from Parkinsonism. Another dopamine receptor blocking drug, oxiperomide, in a dose of 5-10 mg daily has recently been reported to possess promising selective action (Bedard et al., 1978) but its sedative effect makes evaluation difficult.
The substituted benzamides (orthopramides) possess many of the behavioural and biochemical properties associated with dopamine receptor blockade, but in contrast to the phenothiazines and butyrophenones they fail to antagonise dopaminestimulated elevations of striatal adenyl cyclase activity (Jenner et al., 1978) . Thus the short-acting antiemetic metoclopramide in small doses has been used with benefit in the control of levodopa-induced nausea and vomiting without substantially increasing Parkinsonism (Tarsy et al., 1975) , but it does not benefit levodopa-induced dyskinesias. However, the provocation of acute dystonic reactions in 2% of patients (Robinson, 1973) and tardive dyskinesias (Lavy et al., 1978) indicate that metoclopramide can cross the blood brain barrier. Tiapride (N-diethyl aminoethyl methoxy-2-methyl sulphonyl-5-benzamide hydrochloride) is closely related structurally to both metoclopramide and the antipsychotic drug sulpiride and in common with these produces almost no cataleptic effects in rats. It reduces perioral dyskinesias induced by the striatal injection of dopaminergic agonists but, unlike other dopaminergic antagonists, does not reverse the dopamine-induced increase in locomotor activity Naylor, 1975, 1977) . On the basis of this behavioural model, L'Hermitte et al. (1977) have reported that carefully titrated doses of tiapride are effective in selectively reducing peak-dose dyskinesias whereas biphasic dyskinesias were aggravated. In the present study the effect of tiapride in Parkinsonism patients with disabling abnormal involuntary movements has been investigated further.
Patients and methods

SINGLE DOSE STUDIES
Five inpatients with idiopathic Parkinson's disease (mean age 64.4 years, mean duration of disease 13.2 years, mean duration of levodopa treatment 5.8 years) agreed to take part. Four of them were considered to have stage 3 disability on the Hoehn and Yahr classification whereas the other was in stage 2. All were experiencing disabling peak dose 380 chorea and end-of-dose akinesia despite optimum levodopa dosage. Levodopa was stopped for 12 hours when a baseline assessment was performed by scoring each patient (Columbia Disability Scale) at 15 minute intervals over four to six hours after a single morning dose of levodopa given at 0900; dyskinesia severity was also assessed using a four point rating scale at 15 minute intervals. On the next day each patient was given tiapride in a single oral dose 15 minutes before levodopa (three patients were given doses of 25, 50, and 100 mg of tiapride, two patients received 50 and 100 mg of tiapride) and the patient was again observed and scored over a similar four to six hour period. Three patients were also given chlorpromazine 50 mg after an interval of three days and were similarly assessed. Early mornina and "off-period" segmental dystonia is an increasingly frequent and disabling complication of long-term levodopa therapy (Lees et al., 1977) . It is usually confined to the lower limbs but in some patients oromandibular dystonia, spasmodic torticollis, or dystonic hand postures also occur. Although dystonic foot postures were occasionally reported in Parkinson's disease before the advent of levodopa therapy (Duvoisin et al., 1972) they are seen frequently in patients on longterm treatment, and their frequent cessation on withdrawal of the drug indicates a close link with therapy. Paradoxically, increasing the morning dose of levodopa. or the addition of the dopaminergic agonist bromocriptine, tends to ameliorate this disturbance and baclofen, a gamma aminobutyric acid analogue, may also be helpful (Lees et al., 1978) . The inability of tiapride to modify this complication suggests that a subpopulation of dopaminergic receptors or other neurotransmitter systems are involved in its pathogenesis. Despite the inability of tiapride to reduce levodopa-induced abnormal involuntary movements selectively it is possible that other components of the long-term levodopa syndrome, such as isolated visual hallucinations, may respond. The recent reports of selecttive blockade of dyskinesias in patients treated with oxiperomide (Bedard et al., 1978) and the absence of dyskinesias in patients treated solely with bromocriptine, a dopamine receptor agonist (Stern et al., 1979) , should encourage further attempts to inhibit this disabling complication selectively. 
